Novartis' Spinal Muscular Atrophy Treatment Wins UAE Regulatory Nod

03:20 AM EST, 12/21/2025 (MT Newswires) -- Novartis (NOVN.SW) secured clearance from the Emirates Drug Establishment, or EDE, for its spinal muscular atrophy treatment, Itvisma. The approval of the gene therapy for adults and children above two years old was based on clinical trials that demonstrated an improvement in patient motor abilities, as well as its consistent positive safety profile, according to a Dec. 20 release. The pharmaceutical giant noted that the United Arab Emirates-based regulator's move marks the second approval for Itvisma worldwide.